WO 2004/110460 PCT/EP2004/051067

12

Claims

- 1. Pharmaceutical suspension formulation comprising
 - a. particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and
 - c. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.
- 2. Pharmaceutical suspension formulation according to claim 1 consisting of
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - c. ethanol,
 - d. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
 - e. optionally a surfactant.
- 3. Suspension formulation according to any of the proceeding claims containing less than 3% by weight of ethanol.
- 4. Pharmaceutical suspension formulation according to claim 1 consisting of
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - c. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
 - d. a surfactant.
- 5. Suspension formulation according to any of the proceeding claims containing R,R-formoterol.
- Suspension formulation according to any of the proceeding claims containing formoterol furnarate dihydrate.

WO 2004/110460 PCT/EP2004/051067

13

- 7. Suspension formulation according to any of the proceeding claims containing oleic acid as surfactant.
- 8. Suspension formulation according to any of the proceeding claims containing about 0.001 to 0. 1 % (w/w) of oleic acid.
- 9. Suspension formulation according to any of the proceeding claims containing HFA 227 as propellant.
- 10. Suspension formulation according to claim 1 containing disodium chromoglycate at concentrations, which are not therapeutically and/or prophylactically active.
- 11. Suspension formulation according to claim 1, which is administered in once daily dosing regimen.